Literature DB >> 23210122

Comprehensive health assessments for adults with intellectual disability living in the community - weighing up the costs and benefits.

Louisa G Gordon1, Libby Holden, Robert S Ware, Miriam T Taylor, Nicholas G Lennox.   

Abstract

BACKGROUND: Health assessments have beneficial effects on health outcomes for people with intellectual disability living in the community. However, the effect on medical costs is unknown.
METHODS: We utilised Medicare Australia data on consultations, procedures and prescription drugs (including vaccinations) from all participants in a randomised control trial during 2002-03 that examined the effectiveness of a health assessment. Government health costs for adults with intellectual disability who did or did not receive an assessment were compared. Bootstrapping statistics (95% confidence interval) were employed to handle the right-skewed cost data.
RESULTS: Over 12 months, patients receiving health assessments incurred total costs of $4523 (95% CI: $3521 to $5525) similar to those in usual care $4466 (95% CI: $3283 to $5649). Costs were not significantly higher compared with the 12 month pre-intervention period. DISCUSSION: Health assessments for adults with intellectual disability living in the community are encouraged as they produce enhanced patient care but do not increase overall consultation or medication costs.

Entities:  

Mesh:

Year:  2012        PMID: 23210122

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  2 in total

1.  Resource use and cost of annual health checks in primary care for people with intellectual disabilities.

Authors:  M Panca; M Buszewicz; A Strydom; A Hassiotis; C A Welch; R M Hunter
Journal:  J Intellect Disabil Res       Date:  2018-11-21

2.  GPs' opinions of health assessment instruments for people with intellectual disabilities: a qualitative study.

Authors:  Esther J Bakker-van Gijssel; Tim C Olde Hartman; Peter Lbj Lucassen; Francine van den Driessen Mareeuw; Marianne K Dees; Willem Jj Assendelft; Henny Mj van Schrojenstein Lantman-de Valk
Journal:  Br J Gen Pract       Date:  2016-12-19       Impact factor: 5.386

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.